favipiravir for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 all comers meta-analysis
Chang Chen et al. ChiCTR2000030254		RCT	favipiravir	umifenovir (arbidol)	COVID 19 all comers	some concern	120/120	inconclusive	inconclusive 48 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
jRCTs041190120 jRCTs041190120		RCT	favipiravir	favipiravir	COVID 19 all comers	high	44/45	inconclusive	inconclusive 42 % increase in viral clearance ,viral clearance (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias
Lou (FAVIPIRAVIR) ChiCTR2000029544		RCT	favipiravir	standard of care	COVID 19 all comers	some concern	10/10	inconclusive	inconclusive 82 % decrease in viral clearance ,viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
NCT04310228-FAVI (Zhao) ChiCTR2000030894		RCT	favipiravir	tocilizumab	COVID 19 all comers	some concern	-/-	inconclusive	inconclusive 68 % decrease in radiologic improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
Calik		OBS	favipiravir	hydroxychloroquine	COVID 19 all comers	critical	-/-	no results
Cai -FAVIPIRAVIR ChiCTR2000029600		NRa	favipiravir	lopinavir/ritonavir	COVID 19 all comers	NA	35/45	uncontrolled	[uncontrolled] Chest CT improvement (day 14): 91.4% (32/35)
Cai -FAVIPIRAVIR ChiCTR2000029600		NRa	favipiravir	interferon	COVID 19 all comers	NA	35/45	uncontrolled	[uncontrolled] Chest CT improvement (day 14): 91.4% (32/35)
COVID-19 mild to moderate meta-analysis
FACCT Trial NCT04392973		RCT	favipiravir	standard of care	COVID-19 mild to moderate	some concern	125/129	inconclusive	inconclusive 15 % decrease in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
Holubar M NCT04346628		RCT	favipiravir	placebo	COVID-19 mild to moderate	NA	75/74	inconclusive	inconclusive 24 % decrease in viral clearance ,viral clearance (time to event analysis only) (PE)
Shenoy S NCT04529499		RCT	favipiravir	placebo	COVID-19 mild to moderate	high	175/178	inconclusive	inconclusive 1 % decrease in clinical improvement (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias
Shinkai JapicCTI-205238		RCT	favipiravir	placebo	COVID-19 mild to moderate	some concern	107/49	safety concern	inconclusive 40 % increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias statistically significant 18.5-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
Solaymani-Dodaran IRCT20200318046812N1		RCT	favipiravir	lopinavir/ritonavir	COVID-19 mild to moderate	some concern	193/187	inconclusive
AVIFAVIR NCT04434248		RCT	favipiravir	standard of care	COVID 19 hospitalized, COVID-19 mild to moderate	some concern	20/20	suggested	suggested 2.9-fold increase in viral clearance ,viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias Adverse drug reactions to AVIFAVIR were reported in 7/40 (17.5%) patients, including diarrhea, nausea, vomiting, chest pain and an increase in liver transaminase levels. The adverse drug reactions were mild to moderate and caused early discontinuation of the study drug in 2/40 (5.0%) patients.
Dabbous HM NCT04349241		RCT	favipiravir	standard of care	COVID-19 mild to moderate	some concern	50/50	inconclusive
NCT04542694 NCT04542694		RCT	favipiravir	standard of care	COVID-19 mild to moderate	some concern	100/100	suggested	suggested 1.1-fold increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias suggested 12.0-fold increase in viral clearance with a moderate degree of certainty due to some concern in risk of bias
Ruzhentsova T NCT04501783		RCT	favipiravir	standard of care	COVID-19 mild to moderate	some concern	112/56	suggested	suggested 63 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias inconclusive 28 % increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias suggested 28 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias suggested 50 % increase in clinical improvement (7-day) with a moderate degree of certainty due to some concern in risk of bias
Udwadia CTRI/2020/05/025114		RCT	favipiravir	standard of care	COVID 19 hospitalized, COVID-19 mild to moderate	some concern	75/75	safety concern	inconclusive 37 % increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias suggested 75 % increase in clinical improvement,clinical improvement (time to event analysis only),clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias suggested 94 % decrease in mechanical ventilation (time to event analysis only),mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias statistically significant 5.4-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
COVID-19 severe or critically meta-analysis
Kocayigit H		OBS	favipiravir	lopinavir/ritonavir	COVID-19 severe or critically	NA	65/42	inconclusive

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 all comers meta-analysis

COVID-19 mild to moderate meta-analysis

COVID-19 severe or critically meta-analysis